3 Resilient Dividend Stocks to Consider During a Stock Market Decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 19 2025
0mins
Source: NASDAQ.COM
AbbVie and Its Resilience: AbbVie is highlighted as a strong investment due to its robust pipeline and consistent dividend payments, making it likely to withstand market downturns better than many other stocks.
Enterprise Products Partners' Stability: This midstream energy company is noted for its reliable cash flow and long-term contracts, making it a solid choice for dividend investors, especially with a distribution yield of 6.8%.
Pfizer's Attractive Dividend: Despite facing challenges like a patent cliff, Pfizer offers a high dividend yield of 7.15% and has a promising pipeline of products that could mitigate potential sales declines.
Market Outlook and Investment Strategy: The article warns of potential market corrections due to high valuations and suggests considering the top 10 stocks identified by analysts for better investment opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 213.120
Low
223.00
Averages
252.00
High
289.00
Current: 213.120
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified, research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. The aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Duodopa is a levodopa-carbidopa intestinal gel for the treatment of Parkinson's disease. Eye care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AbbVie’s First ADC DECNUPAZ Approved for BPDCN Treatment
- FDA Approval: AbbVie's DECNUPAZ (pivekimab sunirine-pvzy) has received FDA approval as the first antibody-drug conjugate for treating adult patients with BPDCN, marking a significant advancement in blood cancer therapy.
- Clinical Trial Results: In the Phase 1/2 CADENZA trial, 69.7% of 33 newly diagnosed BPDCN patients achieved a composite complete response, with a median duration of response lasting 9.7 months, demonstrating the drug's efficacy and tolerability.
- Expanded Treatment Options: DECNUPAZ provides a new treatment alternative for BPDCN patients, particularly those with relapsed or refractory disease, addressing a critical gap in therapeutic options and holding substantial clinical significance.
- Safety Warnings: The use of DECNUPAZ is associated with serious side effects, including hepatotoxicity and infusion-related reactions, prompting AbbVie to emphasize the need for close monitoring of liver function during treatment to ensure patient safety.
See More
AbbVie Receives FDA Approval for DECNUPAZ
- FDA Approval: AbbVie's DECNUPAZ (pivekimab sunirine-pvzy) has received FDA approval for the treatment of adult patients with BPDCN, an ultra-rare and aggressive hematologic malignancy, marking AbbVie's first ADC approval in blood cancer.
- Clinical Trial Results: In the Phase 1/2 CADENZA trial, 69.7% of 33 newly diagnosed BPDCN patients achieved a composite complete response, with a median duration of response of 9.7 months, demonstrating the significant efficacy of DECNUPAZ.
- Addressing Treatment Needs: BPDCN patients often relapse after intensive chemotherapy, and the approval of DECNUPAZ provides a new treatment option, particularly for relapsed or refractory cases, where 15.7% of patients also achieved remission post-treatment.
- Safety Warnings: The use of DECNUPAZ is associated with serious side effects, including hepatotoxicity, prompting the FDA to issue a boxed warning, emphasizing the need for close monitoring of liver function during treatment to ensure patient safety.
See More
AbbVie’s Drug Approved for Ultra-Rare Blood Cancer Treatment
- Clinical Trial Success: AbbVie's new drug pivekimab sunirine-pvzy (brand name Decnupaz) demonstrated nearly 70% complete remission in treatment-naïve patients during clinical trials, indicating significant efficacy in treating ultra-rare blood cancer and potentially offering new treatment options for patients.
- FDA Approval and Safety Warning: The FDA's approval of the drug comes with a
See More
AbbVie's Decnupaz Receives FDA Approval for Rare Cancer Treatment
- FDA Approval: AbbVie's Decnupaz (pivekimab sunirine) has received FDA approval for treating the ultra-rare hematologic malignancy BPDCN, marking a significant advancement in the company's innovative drug development efforts.
- Clinical Trial Results: The approval is based on the results from the CADENZA trial, which enrolled treatment-naïve or relapsed BPDCN patients, demonstrating a notable complete remission rate that further solidifies AbbVie's position in oncology.
- Dosing Regimen: Decnupaz is administered intravenously at a dose of 0.045 mg/kg every three weeks until disease progression or unacceptable toxicity, ensuring that patients can receive treatment safely over time.
- Safety Warning: The drug comes with a boxed warning for hepatotoxicity, necessitating AbbVie to enhance patient monitoring to mitigate potential safety risks and ensure successful market adoption.
See More
FDA Approves Linzess Label Expansion for Children
- Label Expansion: The FDA's approval for Linzess to treat functional constipation in children aged two and older significantly broadens its application, likely increasing market demand and sales potential in the pediatric segment.
- Clinical Trial Evidence: This approval is supported by a 12-week Phase 3 trial demonstrating that Linzess at a 72 mcg dose significantly improved spontaneous bowel movement frequency compared to placebo, while maintaining a tolerability profile consistent with its established safety record.
- Market Partnerships: Ironwood collaborates with AbbVie for marketing Linzess in the U.S. and Europe, and with Astellas in Japan, enhancing its global market presence and competitive edge in the pharmaceutical industry.
- Focus on Pediatric Health: Given the prevalence of functional constipation among preschool children, this label expansion not only addresses a critical healthcare need but also positions Ironwood for further growth in the pediatric pharmaceutical market, enhancing its brand influence.
See More
Obesity Drug Market Poised for Growth
- Market Potential: The obesity drug market is projected to reach nearly $100 billion by 2030, prompting significant investor interest and confidence, which could lead to substantial stock price increases for companies in this sector.
- Viking Therapeutics Progress: Viking Therapeutics is conducting phase 3 trials for VK-2735, with promising early results suggesting potential market success; strong data could drive stock prices higher, enhancing the company's competitive position in obesity treatment.
- AbbVie's Strategic Development: AbbVie is studying a long-acting amylin analog, with early trials indicating weight loss of 7% to 9%, which could add significant growth potential to its portfolio and strengthen its market position if successfully commercialized.
- Investor Optimism: As demand for obesity drugs rises, the potential success of Viking and AbbVie may attract more investor attention, driving stock prices up, especially against a backdrop of increasing market expectations for new therapies.
See More
AbbVie’s First ADC DECNUPAZ Approved for BPDCN Treatment
- FDA Approval: AbbVie's DECNUPAZ (pivekimab sunirine-pvzy) has received FDA approval as the first antibody-drug conjugate for treating adult patients with BPDCN, marking a significant advancement in blood cancer therapy.
- Clinical Trial Results: In the Phase 1/2 CADENZA trial, 69.7% of 33 newly diagnosed BPDCN patients achieved a composite complete response, with a median duration of response lasting 9.7 months, demonstrating the drug's efficacy and tolerability.
- Expanded Treatment Options: DECNUPAZ provides a new treatment alternative for BPDCN patients, particularly those with relapsed or refractory disease, addressing a critical gap in therapeutic options and holding substantial clinical significance.
- Safety Warnings: The use of DECNUPAZ is associated with serious side effects, including hepatotoxicity and infusion-related reactions, prompting AbbVie to emphasize the need for close monitoring of liver function during treatment to ensure patient safety.
See More
AbbVie Receives FDA Approval for DECNUPAZ
- FDA Approval: AbbVie's DECNUPAZ (pivekimab sunirine-pvzy) has received FDA approval for the treatment of adult patients with BPDCN, an ultra-rare and aggressive hematologic malignancy, marking AbbVie's first ADC approval in blood cancer.
- Clinical Trial Results: In the Phase 1/2 CADENZA trial, 69.7% of 33 newly diagnosed BPDCN patients achieved a composite complete response, with a median duration of response of 9.7 months, demonstrating the significant efficacy of DECNUPAZ.
- Addressing Treatment Needs: BPDCN patients often relapse after intensive chemotherapy, and the approval of DECNUPAZ provides a new treatment option, particularly for relapsed or refractory cases, where 15.7% of patients also achieved remission post-treatment.
- Safety Warnings: The use of DECNUPAZ is associated with serious side effects, including hepatotoxicity, prompting the FDA to issue a boxed warning, emphasizing the need for close monitoring of liver function during treatment to ensure patient safety.
See More
AbbVie’s Drug Approved for Ultra-Rare Blood Cancer Treatment
- Clinical Trial Success: AbbVie's new drug pivekimab sunirine-pvzy (brand name Decnupaz) demonstrated nearly 70% complete remission in treatment-naïve patients during clinical trials, indicating significant efficacy in treating ultra-rare blood cancer and potentially offering new treatment options for patients.
- FDA Approval and Safety Warning: The FDA's approval of the drug comes with a
See More
AbbVie's Decnupaz Receives FDA Approval for Rare Cancer Treatment
- FDA Approval: AbbVie's Decnupaz (pivekimab sunirine) has received FDA approval for treating the ultra-rare hematologic malignancy BPDCN, marking a significant advancement in the company's innovative drug development efforts.
- Clinical Trial Results: The approval is based on the results from the CADENZA trial, which enrolled treatment-naïve or relapsed BPDCN patients, demonstrating a notable complete remission rate that further solidifies AbbVie's position in oncology.
- Dosing Regimen: Decnupaz is administered intravenously at a dose of 0.045 mg/kg every three weeks until disease progression or unacceptable toxicity, ensuring that patients can receive treatment safely over time.
- Safety Warning: The drug comes with a boxed warning for hepatotoxicity, necessitating AbbVie to enhance patient monitoring to mitigate potential safety risks and ensure successful market adoption.
See More
FDA Approves Linzess Label Expansion for Children
- Label Expansion: The FDA's approval for Linzess to treat functional constipation in children aged two and older significantly broadens its application, likely increasing market demand and sales potential in the pediatric segment.
- Clinical Trial Evidence: This approval is supported by a 12-week Phase 3 trial demonstrating that Linzess at a 72 mcg dose significantly improved spontaneous bowel movement frequency compared to placebo, while maintaining a tolerability profile consistent with its established safety record.
- Market Partnerships: Ironwood collaborates with AbbVie for marketing Linzess in the U.S. and Europe, and with Astellas in Japan, enhancing its global market presence and competitive edge in the pharmaceutical industry.
- Focus on Pediatric Health: Given the prevalence of functional constipation among preschool children, this label expansion not only addresses a critical healthcare need but also positions Ironwood for further growth in the pediatric pharmaceutical market, enhancing its brand influence.
See More
Obesity Drug Market Poised for Growth
- Market Potential: The obesity drug market is projected to reach nearly $100 billion by 2030, prompting significant investor interest and confidence, which could lead to substantial stock price increases for companies in this sector.
- Viking Therapeutics Progress: Viking Therapeutics is conducting phase 3 trials for VK-2735, with promising early results suggesting potential market success; strong data could drive stock prices higher, enhancing the company's competitive position in obesity treatment.
- AbbVie's Strategic Development: AbbVie is studying a long-acting amylin analog, with early trials indicating weight loss of 7% to 9%, which could add significant growth potential to its portfolio and strengthen its market position if successfully commercialized.
- Investor Optimism: As demand for obesity drugs rises, the potential success of Viking and AbbVie may attract more investor attention, driving stock prices up, especially against a backdrop of increasing market expectations for new therapies.
See More
